Khaled Barakat

Easy tissue expansion of prelaminated mucosa-lined flaps for cheek reconstruction in a canine model.

The effect of low-molecular-weight heparin in the survival of a rabbit congested skin flap.

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.

Clinical outcome in cranioplasty: critical review in long-term follow-up.

Evaluation of 45S5 bioactive glass combined as a bone substitute in the reconstruction of critical size calvarial defects in rabbits.

Hypertelorism: the importance of three-dimensional imaging and trends in the surgical correction by facial bipartition.

Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist.

Melanocortin subtype 4 receptor agonists: structure-activity relationships about the 4-alkyl piperidine core.

Melanotic neuroectodermal tumor of infancy: review of literature and case report.

Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach.

Electrostatic contributions to colchicine binding within tubulin isotypes.

Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.

Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping.

Relaxed complex scheme suggests novel inhibitors for the lyase activity of DNA polymerase beta.

Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant.

Discovery of small molecule inhibitors that interact with γ-tubulin.

DNA polymerase beta (pol β) inhibitors: a comprehensive overview.

DNA Repair Inhibitors: Our Last Disposal to Improve Cancer Therapy.

Computational predictions of volatile anesthetic interactions with the microtubule cytoskeleton: implications for side effects of general anesthesia.

DNA repair inhibitors: the next major step to improve cancer therapy.

Modeling the yew tree tubulin and a comparison of its interaction with paclitaxel to human tubulin.

Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction.

Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.

A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant.

Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design.

Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus.

A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes.

Vaccine adjuvants--understanding molecular mechanisms to improve vaccines.

A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.

Human structural proteome-wide characterization of Cyclosporine A targets.

Thermoplastic vestibuloplasty: a novel technique for treatment of lip and cheek adhesion.

IL-28B is a key regulator of B- and T-cell vaccine responses against influenza.

Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.

Human PD-1 binds differently to its human ligands: a comprehensive modeling study.

Discovery of Novel Peptidomimetics as Irreversible CHIKV NsP2 Protease Inhibitors Using Quantum Mechanical-Based Ligand Descriptors.

Entropy in bimolecular simulations: A comprehensive review of atomic fluctuations-based methods.

New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.